6:15 PM
 | 
Dec 18, 2012
 |  BC Extra  |  Clinical News

Allon plummets on davunetide update

Allon Therapeutics Inc. (TSX:NPC) fell C$0.41 (94%) to C$0.03 on Tuesday after the company said it will not allocate any additional capital to R&D for davunetide and will take...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >